Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort

Zitt, Emanuel; Fischer, Anton; Lhotta, Karl; Concin, Hans; Nagel, Gabriële

doi:10.1038/s41598-020-64587-z

Cited by 41 publications

(33 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A more detailed description of the program is reported elsewhere. 9,19,20 Because an overnight fast was part of the protocol only from January 1, 1988, onward, we excluded 8073 participants (4.4%) who did not have an examination with a blood sample obtained in fasting status. Of the remaining participants, we excluded another 874 (0.5%) owing to missing BMI, glucose, or triglyceride values, resulting in a final analysis population of 176 420 participants initially free of ESKD at the baseline examination, with complete information on exposure, mediator, outcome variables, and covariates.…”

Section: Data Source and Study Populationmentioning

confidence: 99%

The Triglyceride-Glucose Index and Obesity-Related Risk of End-Stage Kidney Disease in Austrian Adults

Fritz

Brozek²,

Concin³

et al. 2021

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

IMPORTANCE It is unknown whether the triglyceride-glucose (TyG) index as a measure of insulin resistance is associated with the risk of developing end-stage kidney disease (ESKD). Because individuals who are overweight or obese often develop insulin resistance, mediation of the association between body mass index (BMI) and ESKD risk through the TyG index seems plausible but has not been investigated. OBJECTIVE To evaluate whether the TyG index is associated with ESKD risk and, if so, to what extent the TyG index mediates the association between BMI and ESKD. DESIGN, SETTING, AND PARTICIPANTS A total of 176 420 individuals were recruited during routine health examinations to participate in the Austrian Vorarlberg Health Monitoring and Promotion Program (VHM&PP), a prospective, population-based cohort study with participant

show abstract

Section: Data Source and Study Populationmentioning

confidence: 99%

The Triglyceride-Glucose Index and Obesity-Related Risk of End-Stage Kidney Disease in Austrian Adults

Fritz

Brozek²,

Concin³

et al. 2021

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…Uric acid (UA) has been a subject of medical interest for many years. The prevalence of hyperuricemia ranges between 5-16% in the general populations of Western Europe, reaching 85% of the Marshall Islands population [1,2]. High serum uric acid (SUA) concentration is linked with the development of gout; cardiovascular diseases (CVD), including coronary artery disease (CAD); stroke and hypertension; as well as diabetes and the accelerated progression of atherosclerosis [3][4][5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Serum Uric Acid Is a Weak Independent Predictor of Overall Survival in Older Adults

Winder

Owczarek

Mossakowska

et al. 2021

JCM

View full text Add to dashboard Cite

Hyperuricemia accompanies many pathologies that contribute to overall death rate. The population-based multifaceted study of older adults in Poland made it possible to assess the effect of serum uric acid (SUA) on overall mortality. The PolSenior study performed between 2007–2011 included 3926 participants aged 65 years or above (mean age 79 ± 9 years) not treated with xanthin oxidase inhibitors (XOI) who were stratified by sex and SUA concentration into six subgroups increasing by 1 mg/dL. In 2019, survival data were retrieved from the population register. The crude risk of death was significantly higher in men and women with SUA ≥ 7 mg/dL. After adjustment to statistically significant factors, SUA remained a risk factor of death in men with SUA ≥ 8 mg/dL only, potentially due to the limited number of women with high SUA levels. Furthermore, age, heart failure, diabetes, and activities of daily living ≤ 4 pts were identified as factors increasing mortality risk regardless of sex. The risk of death increased also with smoking, past stroke, COPD/asthma, and hs-CRP > 3 mg/dL for men; and eGFR < 45 mL/min/1.73 m2, mini nutritional assessment ≤ 7 pts, and loop diuretics use for women. Mild hyperuricemia is a significant health status marker and an independent risk factor for overall mortality in older Caucasians not receiving XOI. Increased mortality is mostly limited to subjects with SUA levels ≥ 8 mg/dL.

show abstract

“…Hyperuricemia is a metabolic disorder characterized by a high UA level in serum due to an imbalance between UA production and excretion and causes gout [14]. Recently, the prevalence of hyperuricemia has continuously increased worldwide [31]. Currently, there are a limited number of drugs available for treating hyperuricemia, and many of these drugs have side effects.…”

Section: Discussionmentioning

confidence: 99%

Antihyperuricemic Effect of Dendropanax morbifera Leaf Extract in Rodent Models

Lee

Kim

Han

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Dendropanax morbifera is a well-known traditional medicine used in China and Korea to treat intestinal disorders, urosis, diuresis, and chronic glomerulonephritis. Hyperuricemia is a metabolic disorder characterized by a high uric acid level in serum due to an imbalance between uric acid production and excretion and causes gout. Recently, the prevalence of hyperuricemia worldwide has been continuously increasing. Xanthine oxidase (XOD) inhibitors (allopurinol (ALP) and febuxostat) and uricosuric agents (benzbromarone and probenecid) are used to treat hyperuricemia clinically. However, because these drugs are poorly tolerated and cause side effects, such as kidney diseases, hepatotoxicity, gastrointestinal symptoms, and hypersensitivity syndrome, only a limited number of drugs are available. We investigated the antihyperuricemic effects of Dendropanax morbifera leaf ethanol extract (DMLE) and its underlying mechanisms of action through in vitro and in vivo studies. We evaluated uric acid levels in serum and urine, and xanthine oxidase (XOD) inhibition activity in the serum and liver tissue of a hyperuricemic rat model of potassium oxonate (PO)-induced hyperuricemic rats. In vitro study, XOD-inhibitory activity was the lowest among the test substances at the IC50 of ALP. However, the IC50 of DMLE-70 was significantly low compared with that of other DMLEs ( p < 0.05 ). In PO-induced hyperuricemic rats, uric acid (UA) levels in serum and urine were significantly reduced in all DMLE-70 and allopurinol-treated (ALT) groups than in the PC group ( p < 0.05 ). UA levels in urine were lower than those in serum in all DME groups. In PO-induced hyperuricemic rats, DMEE-200 reduced UA concentration in serum and increased UA excretion in the urine. These findings suggest that DMLE exerts antihyperuricemic and uricosuric effects on promoting UA excretion by enhanced secretion and inhibition of UA reabsorption in the kidneys. Thus, DMLE may be a potential treatment for hyperuricemia and gout.

show abstract

Sex- and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort

Cited by 41 publications

References 35 publications

The Triglyceride-Glucose Index and Obesity-Related Risk of End-Stage Kidney Disease in Austrian Adults

The Triglyceride-Glucose Index and Obesity-Related Risk of End-Stage Kidney Disease in Austrian Adults

Serum Uric Acid Is a Weak Independent Predictor of Overall Survival in Older Adults

Antihyperuricemic Effect of Dendropanax morbifera Leaf Extract in Rodent Models

Contact Info

Product

Resources

About